Rabbit Polyclonal DPY3 Antibody

The DPYD (Dihydropyrimidine Dehydrogenase) enzyme, encoded by the *DPYD* gene, plays a critical role in pyrimidine metabolism by catalyzing the reduction of uracil and thymine. It is also essential for the inactivation of fluoropyrimidine chemotherapeutic agents like 5-fluorouracil (5-FU). Genetic variants or deficiencies in DPYD activity can lead to severe drug toxicity, making DPYD a key pharmacogenetic biomarker for personalized cancer therapy. Antibodies targeting DPYD are widely used in research and diagnostics to assess protein expression levels, identify functional deficiencies, and study enzyme regulation. These antibodies are applied in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme activity assays. Recent studies also explore DPYD's role in metabolic disorders and its potential as a therapeutic target. Commercially available DPYD antibodies are typically validated for specificity against human isoforms, with some targeting specific domains or phosphorylation sites. Researchers emphasize the importance of antibody validation using DPYD-deficient cell lines or knockout models to ensure accuracy in clinical and experimental settings. Ongoing efforts aim to improve antibody sensitivity and develop standardized assays for DPYD quantification in patient samples.